Mynd Analytics
EMMAOTCOther · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $12.5M | $16.7M | $29.6M | $18.4M | $20.6M | $23.2M |
| Operating income | $231,000 | −$1.9M | $3.5M | −$6.6M | −$6.1M | −$32,000 |
| Net income | −$7.5M | −$6.5M | −$3.7M | −$10.6M | −$15.9M | $1.4M |
| Total assets | $21.4M | $23.6M | $35.2M | $48.2M | $56.7M | $59.5M |
| Total liabilities | $85.0M | $80.1M | $82.9M | $82.3M | $78.2M | $64.7M |
| Equity | −$63.6M | −$56.5M | −$47.8M | −$34.1M | −$21.4M | −$5.2M |
| EPS (diluted) | $-0.12 | $-0.10 | $-0.07 | $-0.21 | $-0.32 | — |
| Shares out. | 63.9M | 61.8M | 50.9M | 49.3M | 49.3M | 49.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 1.9%
- Net margin
- −60.2%
- Return on equity
- 11.8%
- Return on assets
- −35.0%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 396.7%
- Debt / equity
- —
- Book value / share
- $-1.00
- Revenue growth (YoY)
- −25.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -60.55distress
- Accruals / assets
- −34.9%clean
- Beneish M-Score
- -4.02normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Operating margin is positive
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2025
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2024
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2024
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2024
- NT 10-Qmissed a reporting deadline ↗May 17, 2021
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2021
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Lim Seah H.Passive (13G)Feb 4, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1,633 | 1.0 | 0.0% |
| Apr 30, 2026 | 1,633 | 1.0 | 0.0% |
| Apr 15, 2026 | 1,633 | 1.0 | -98.7% |
| Mar 31, 2026 | 127,097 | 7.4 | -0.4% |
| Mar 13, 2026 | 127,555 | 20.4 | -0.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 15, 2026
- Director / officer changeApr 17, 2026
- Director / officer changeApr 14, 2026
- Results of operationsMar 31, 2026
- Entered a material agreementMar 4, 2026
- Entered a material agreement · Other material eventDec 31, 2025
- Entered a material agreement · New financial obligation · Unregistered equity saleDec 22, 2025
- Director / officer changeDec 19, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KCURRENT REPORTMay 15, 2026
- 10-QMay 15, 2026
- 3Apr 21, 2026
- 8-KCURRENT REPORTApr 17, 2026
- 8-KCURRENT REPORTApr 14, 2026
- 8-KCURRENT REPORTMar 31, 2026
- 10-KMar 31, 2026
- 8-KCURRENT REPORTMar 4, 2026
- 8-KCURRENT REPORTDec 31, 2025
- 8-KCURRENT REPORTDec 22, 2025
- 8-KCURRENT REPORTDec 19, 2025
- 8-KCURRENT REPORTNov 14, 2025
- 10-QNov 14, 2025
- 8-KCURRENT REPORTAug 14, 2025
- 10-QAug 14, 2025
Corporate family
Spin-offs from Mynd Analytics (1)
- Telemynd, Inc.completedJun 14, 2019details
From the spin-off filings we track. Follow a company to walk its own history.